Primary Humoral Immunodeficiencies and Bronchiectasis in Adults

dc.contributor.author
Suárez Cuartín, Guillermo Rafael
dc.contributor.author
Lores, Carmen
dc.contributor.author
Gómez Olivas, José Daniel
dc.contributor.author
Oscullo, Grace
dc.contributor.author
Martínez García, Miguel Ángel
dc.date.accessioned
2026-02-20T06:21:15Z
dc.date.available
2026-02-20T06:21:15Z
dc.date.issued
2026-02-19T11:27:47Z
dc.date.issued
2026-02-19T11:27:47Z
dc.date.issued
2025-12-26
dc.date.issued
2026-02-09T12:19:29Z
dc.identifier
https://hdl.handle.net/2445/227065
dc.identifier
41517428
dc.identifier.uri
https://hdl.handle.net/2445/227065
dc.description.abstract
Primary humoral immunodeficiencies are a heterogeneous group of disorders defined by quantitative and/or functional defects in one or more immunoglobulin classes, often with associated cellular immune abnormalities. Their link with bronchiectasis, whose prevalence varies across specific defects, is largely driven by recurrent respiratory infections. Selective Immunoglobulin-(Ig)A deficiency and IgG2 subclass deficiency are the most frequent forms, but common variable immunodeficiency (CVID) is the condition most often associated with bronchiectasis and is usually diagnosed earlier because of its characteristic phenotype. In contrast, the contribution of isolated IgA deficiency or selective IgG subclass deficiencies to bronchiectasis remains controversial. Other reported associations include X-linked agammaglobulinemia, selective IgM or IgG deficiency, and rarer entities such as selective IgE deficiency, unclassified hypogammaglobulinemia, specific antibody deficiency, specific polysaccharide antibody deficiency, and heavy- or light-chain deficiencies. Current bronchiectasis guidelines recommend measurement of serum immunoglobulins and IgG subclasses in patients with compatible features, recurrent infections, or no clear etiology before labeling disease as idiopathic. Identifying immunoglobulin defects is clinically important because they represent treatable traits. The potential role of emerging therapies such as the DPP1 inhibitor brensocatib in immunodeficiency-related bronchiectasis remains uncertain, and ongoing registries will be key to clarifying these relationships.
dc.format
16 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
MDPI AG
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/jcm15010179
dc.relation
Journal of Clinical Medicine, 2025, vol. 15, issue. 1, p. 179
dc.relation
https://doi.org/10.3390/jcm15010179
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/embargoedAccess
dc.subject
Malalties bronquials
dc.subject
Síndrome del destret respiratori de l'adult
dc.subject
Bronchial diseases
dc.subject
Adult respiratory distress syndrome
dc.title
Primary Humoral Immunodeficiencies and Bronchiectasis in Adults
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Files in this item

FilesSizeFormatView

There are no files associated with this item.